A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.

NCT Number	NCT07544589
Lead Sponsor	Dispatch Biotherapeutics Collaborators: Bristol-Myers Squibb
Conditions	Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Enrollment	66 participants
Start Date	2026-04
Primary Completion	2046-04 (estimated)
Study Completion	2046-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-29